CU20120099A7 - Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos - Google Patents

Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos

Info

Publication number
CU20120099A7
CU20120099A7 CU20120099A CU20120099A CU20120099A7 CU 20120099 A7 CU20120099 A7 CU 20120099A7 CU 20120099 A CU20120099 A CU 20120099A CU 20120099 A CU20120099 A CU 20120099A CU 20120099 A7 CU20120099 A7 CU 20120099A7
Authority
CU
Cuba
Prior art keywords
pirazina
derivatives
treatment
neurological disorders
formula
Prior art date
Application number
CU20120099A
Other languages
English (en)
Inventor
Siem Jacob Veenstra
Marina Tintelnot-Blomley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120099(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20120099A7 publication Critical patent/CU20120099A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a novedosos compuestos heterocíclicos de la fórmula (I): ESPACIO PARA LA FÓRMULA en donde todas las variables son como se definen en la memoria descriptiva, en forma libre oen forma de sal, a su preparación, a su uso médico, y a medicamentos que los comprenden.
CU20120099A 2009-12-31 2012-06-25 Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos CU20120099A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29172409P 2009-12-31 2009-12-31

Publications (1)

Publication Number Publication Date
CU20120099A7 true CU20120099A7 (es) 2012-07-31

Family

ID=43598456

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120099A CU20120099A7 (es) 2009-12-31 2012-06-25 Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos

Country Status (27)

Country Link
US (2) US20120277244A1 (es)
EP (1) EP2519515B1 (es)
JP (1) JP5600754B2 (es)
KR (1) KR101419157B1 (es)
CN (1) CN102712621B (es)
AU (1) AU2010338365B2 (es)
BR (1) BR112012015916A2 (es)
CA (1) CA2785341A1 (es)
CL (1) CL2012001762A1 (es)
CR (1) CR20120332A (es)
CU (1) CU20120099A7 (es)
EA (1) EA201200952A1 (es)
EC (1) ECSP12012065A (es)
ES (1) ES2445536T3 (es)
GT (1) GT201200219A (es)
HN (1) HN2012001413A (es)
IL (1) IL220268A0 (es)
MX (1) MX2012007754A (es)
NZ (1) NZ600136A (es)
PE (1) PE20121640A1 (es)
PH (1) PH12012501007A1 (es)
PL (1) PL2519515T3 (es)
PT (1) PT2519515E (es)
SG (1) SG181431A1 (es)
TN (1) TN2012000249A1 (es)
WO (1) WO2011080176A1 (es)
ZA (1) ZA201203614B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612854B1 (en) 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
UA110467C2 (uk) 2009-12-11 2016-01-12 Шионогі Енд Ко., Лтд. Похідні оксазину
CN102918036A (zh) * 2010-06-09 2013-02-06 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物
AU2011263797B2 (en) 2010-06-09 2014-06-05 Janssen Pharmaceutica Nv 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE)
JP2013529664A (ja) * 2010-06-28 2013-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アルツハイマー病および他の型の認知症の処置に有用な３−アミノ−５，６−ジヒドロ−１ｈ−ピラジン−２−オン誘導体
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
JP5834091B2 (ja) 2010-12-22 2015-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ベータ−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な５，６−ジヒドロ−イミダゾ［１，２−ａ］ピラジン−８−イルアミン誘導体
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
CA2824220C (en) 2011-01-13 2020-09-01 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EA201391033A1 (ru) * 2011-01-13 2014-01-30 Новартис Аг Ингибиторы bace-2 для лечения метаболических расстройств
ES2558779T3 (es) 2011-03-01 2016-02-08 Janssen Pharmaceutica, N.V. Derivados de 6,7-dihidro-pirazolo[1,5-a]piracin-4-ilamina útiles como inhibidores de ß-secretasa (BACE)
JP5853035B2 (ja) 2011-03-09 2016-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な３，４−ジヒドロ−ピロロ［１，２−ａ］ピラジン−１−イルアミン誘導体
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
MX2013011947A (es) 2011-04-13 2014-01-16 Merck Sharp & Dohme Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso.
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
CA2894919A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. C5,c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors, compositions, and their use
AU2014280124B2 (en) 2013-06-12 2018-11-01 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE)
CA2911693C (en) 2013-06-12 2021-08-24 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
CA2912156C (en) 2013-06-12 2021-07-20 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
CA2967164A1 (en) 2014-12-18 2016-06-23 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase
CN107011134B (zh) * 2017-04-28 2021-02-05 浙江中欣氟材股份有限公司 一种2-氟-5-溴苯乙酮的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (es) 1968-08-31 1970-03-03
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
EP1363702A4 (en) * 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7728025B2 (en) 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
US20050215884A1 (en) * 2004-02-27 2005-09-29 Greicius Michael D Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI
EP2612854B1 (en) * 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
EP2774925B1 (en) * 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP-binding cassette transporters
WO2008079933A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CN102918036A (zh) * 2010-06-09 2013-02-06 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物
JP2013529664A (ja) * 2010-06-28 2013-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アルツハイマー病および他の型の認知症の処置に有用な３−アミノ−５，６−ジヒドロ−１ｈ−ピラジン−２−オン誘導体

Also Published As

Publication number Publication date
CA2785341A1 (en) 2011-07-07
WO2011080176A1 (en) 2011-07-07
AU2010338365A1 (en) 2012-06-07
KR20120102795A (ko) 2012-09-18
ZA201203614B (en) 2013-01-30
AU2010338365B2 (en) 2014-01-30
HK1172023A1 (en) 2013-04-12
EP2519515B1 (en) 2013-11-06
EP2519515A1 (en) 2012-11-07
SG181431A1 (en) 2012-07-30
PT2519515E (pt) 2014-02-17
PL2519515T3 (pl) 2014-04-30
US20150322038A1 (en) 2015-11-12
IL220268A0 (en) 2012-07-31
GT201200219A (es) 2013-10-10
KR101419157B1 (ko) 2014-07-11
PH12012501007A1 (en) 2013-01-14
CN102712621A (zh) 2012-10-03
BR112012015916A2 (pt) 2017-04-25
US20120277244A1 (en) 2012-11-01
JP5600754B2 (ja) 2014-10-01
CN102712621B (zh) 2015-03-11
TN2012000249A1 (en) 2013-12-12
ES2445536T3 (es) 2014-03-03
CR20120332A (es) 2012-07-12
JP2013516395A (ja) 2013-05-13
CL2012001762A1 (es) 2012-12-21
ECSP12012065A (es) 2012-08-31
EA201200952A1 (ru) 2013-02-28
MX2012007754A (es) 2012-08-01
NZ600136A (en) 2013-09-27
PE20121640A1 (es) 2012-12-17
HN2012001413A (es) 2015-03-23

Similar Documents

Publication Publication Date Title
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
UY33883A (es) Novedosos derivados heterocíclicos
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
UY31651A1 (es) Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
UY33199A (es) 5-alquinil-pirimidinas.
DOP2013000027A (es) Derivados de tetrahidro-pirido-pirimidina
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY33176A (es) Derivados de oxazolopirimidina sustituida en 2, 5, 7.
UY32404A (es) 4-aril-butan-1,3-diamidas
ECSP11011454A (es) 5-alquinil-piridinas
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
UY33181A (es) Derivados de oxazolopirimidina 2,5-sustituidos.
CR20150092A (es) Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo
ECSP12012110A (es) 5-alquinil-pirimidinas
HN2012000132A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos
CU24047B1 (es) Derivados de oxazina útiles en el tratamiento de los trastornos neurológicos
CU20130108A7 (es) Novedosos derivados heterocíclicos
CR20120083A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurologicos